Nohla is leading the development of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases.
2
Ongoing Phase 2 Trials
100
Patients Treated w/NLA101
15
Years of Research
70
WW Stem Cell Transplants Per Year
Ongoing Trials
Dilanubicel (NLA101) is currently under evaluation in two large randomized, multi-center Phase 2 studies. The first is an ongoing Phase 2b study in the US for patients with acute leukemia, MDS or CML undergoing a myeloablative CBT. The second Phase 2 trial is a global study intended to enroll 220 patients with AML who are at risk for neutropenia following high dose chemotherapy.
Patient Stories
Over 100 patients and counting have been treated with dilanubicel (NLA101) across four clinical trials, bringing hope to those with limited or no treatment options.
